Screener
ADMA Biologics ADMA ADMA Bio Manufacturing — Gain On Sale Of Investments
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:GainOnSaleOfInvestments.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| (in thousands) | ADMA Bio Manufacturing | Plasma Collection Centers | Total |
|---|---|---|---|
| Cost of product revenue | 37,564 | 554 | 38,118 |
| Research and development | 6,014 | - | 6,014 |
| Plasma center operating expenses | - | 1,026 | 1,026 |
| Gain on sale of plasma centers | - | - | - |
| Selling, marketing and distribution | 7,634 | - | 7,634 |
| Depreciation and amortization expense | 1,281 | 499 | 1,780 |
| General and administrative expense | 8,340 | - | 8,340 |
| Other income (expense), net | (20) | 150 | 130 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's ADMA bio manufacturing — gain on sale of investments?
- ADMA Biologics (ADMA) reported ADMA bio manufacturing — gain on sale of investments of $0 in Q2 2026.
- What does ADMA bio manufacturing — gain on sale of investments mean?
- Represents the realized profit from the disposal of financial assets or equity holdings held by the manufacturing segment. It serves as a non-operating item that can impact net income but does not reflect core operational performance.
Ask your AI about ADMA Biologics's adma bio manufacturing — gain on sale of investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude